The main indication for recombinant activated factor VII (rFVIIa) is the treatment of patients with hemophilia or other hemostatic disturbances. Additionally, rFVIIa has been considered as a universal hemostatic agent prompting its use in the management of severe uncontrolled bleeding in patients without pre-existing coagulopathies. Authors report their own experience in the beneficial effect of rFVIIa (NovoSeven, NovoNordisk, Denmark) administration in a patient with severe bleeding from the nasopharyngeal region after extensive fronto-basal injuries. After one dose of NovoSeven (2.4 mg - 40 microg/kg of body weight) reduction in bleeding, normalization of hemostasis parameters and hemodynamic stabilization of the patient were achieved.